Guardant Health, Inc.
For the period ended Mar 31, 2025. Filed Apr 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Apr 30, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Insider trading arrangements
During the fiscal quarter ended March 31, 2025, none of our directors or officers adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, except as described in the table below:
| Name and Title of Insider · Adoption, Modification or Termination · Applicable Date · Duration of Trading Arrangement · Rule 10b5-1 Trading Arrangement?(Y / N) (1) · Aggregate Number of Securities Subject to the Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Myrtle Potter, Director | Adoption | 3/15/2025 | 6/13/2025 – 6/22/2026 | Y | Indeterminable | (2) |
(1)Denotes whether the trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) when adopted.
(2)Ms. Potter’s 10b5-1 trading plan provides for the sale of (i)78 shares of our common stock plus (ii)(a)2,678 shares of our common stock underlying certain restricted stock unit awards that will vest during the duration of the trading arrangement and (b) 37% of an indeterminable number of shares of our common stock underlying certain restricted stock unit awards that will be granted and vest during the duration of the trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.